Ecuador ARCSA Registry and Market Analysis: Reading the Public Database

Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

General provision SEGUNDA of the new regulation requires ARCSA to publish on its website the registration information for medical devices that are valid, suspended and cancelled, giving manufacturers in the Chinese mainland an official entry point for competitor and compliance intelligence. Note that the number of product records in the public database does not equal the number of registration certificates; the former is roughly 15 times the latter, a gap that arises from the one-certificate-many-models system and the combined holding of kits and sets under Articles 14 and 15 of the new regulation.

2. Legal basis

Regulation	Reference number	Publication date	Articles
Substitute Technical Health Regulation for the Health Registration, Control and Surveillance of Medical Devices for Human Use	Resolucion ARCSA-DE-2026-003-DASP	Signed 2026-04-28	General provision SEGUNDA (information disclosure and consequences of suspension and cancellation)
Same as above	Same as above	Same as above	Article 17 (registration number and validity), Articles 14 and 15 (many models per certificate; kits and sets)
Same as above	Same as above	Same as above	Article 10 and Article 32 (entry limits)
Ley Organica de Salud	Ley 67/2006, Registro Oficial Suplemento 423	2006-12-22	Article 132

Data nature statement: the market size and registry statistics mentioned in this article, such as roughly 326,000 product records and roughly 22,000 registration certificates, are third-party snapshot analyses of the public ARCSA registration database, expressed as industry statistics rather than data officially released by ARCSA. Any citation should state the snapshot date and the statistical basis, and the current disclosures on the ARCSA website always take precedence.

3. Expert insights

Insight one: the one-certificate-many-models rule is the key to the structure of the registry data. Article 14 allows several devices to be registered under one certificate, provided they share the same device type, risk class, product owner, manufacturer and intended purpose; Article 15 further allows kits (set/kit) and systems to be held under a single certificate; Article 16 provides that the validity of a kit follows the member with the shortest service life and its class follows the member with the highest risk. One certificate can therefore cover dozens of models, which is precisely why product records far outnumber registration certificates.

Insight two: the entry limits appear in Article 10 and Article 32, with different scopes of application but identical values. Article 10 applies to standard registration and changes, with limits of 100 entries for devices and 50 for in vitro diagnostics; Article 32 applies to simplified registration, with limits of 100 entries for DMI, DMNI and DMA devices and 50 for DMDIV.

Correction note: some materials misstate the 50-entry limit as 50 products of Class IV risk. The official text reads 50 entries for DMDIV (in vitro diagnostic medical devices), which is unrelated to risk class.

Insight three: the information disclosure duty is a two-way compliance tool. General provision SEGUNDA requires ARCSA to publish valid, suspended and cancelled registrations, and it provides that suspension or cancellation of a certificate implies a prohibition on its manufacture, import and export, immediate withdrawal from the market, and confiscation. For companies this is both a source of competitor intelligence and a means of self-checking channel risk: the registration status of distributors and license holders should be checked periodically.

Insight four: differences in statistical basis amplify misjudgment. Measuring how many registrations a brand holds by product records inflates the result by roughly an order of magnitude; counting registration certificates is the comparable basis. Competitor benchmarking should use counts of unique registration numbers.

Insight five: the registry has no country-of-origin field, so the visibility of manufacturers in the Chinese mainland depends on brand matching. Reverse matching by brand is the main method for analyzing their installed base, and this understates Chinese OEM capacity registered under local distributors own private labels.

4. Practical recommendations

Use registration certificate counts (unique registration numbers) uniformly for competitor benchmarking, never product record counts.
Build a brand-to-generic-name mapping table using UMDNS and GMDN to improve retrievability in the registry.
Check the registration status of license holders and distributors periodically, guarding against circulation interruptions caused by suspension or cancellation.
Design the submission architecture around one-certificate-many-models to spread official fees across a model series.
State the snapshot date and statistical basis whenever citing registry data, avoiding mixed bases.

5. Verification checklist

□ The snapshot date and statistical basis of registry statistics have been confirmed
□ Competitor benchmarking uses counts of unique registration numbers
□ A brand-to-generic-name mapping table has been established
□ The registration status of license holders and distributors is checked periodically
□ The submission architecture follows the one-certificate-many-models design of Articles 14 and 15
□ The entry limits of Article 10 (standard and changes) and Article 32 (simplified) have been distinguished

Regulatory information verified as of October 29, 2026

GRZAN core service lines

Global registration access: EU CE (MDR/IVDR), US FDA (510(k)/De Novo/PMA), UK UKCA, Australia TGA, Canada Health Canada, Brazil ANVISA and Russia RZN, together with pre-market registration pathway planning and submission execution across Latin America, Southeast Asia and the Middle East.
Authorized representative services: EU EC REP, UK RP, Swiss CH REP, Australian sponsor and US Agent holding and representation services, with support for neutral license-holder structures.
Quality system compliance: ISO 13485 establishment and maintenance, MDSAP audit preparation, GMP conformity coaching, and technical documentation (TD) drafting and remediation.
Clinical and evaluation support: clinical evaluation plans (CEP) and reports (CER), equivalence argumentation, PMCF planning and execution, and IVD performance evaluation.
Post-market compliance: vigilance and adverse event reporting, FSCA and recall execution, registration change and renewal management, and maintenance of national regulatory databases.

Why manufacturers choose GRZAN

Local regulatory teams: target-market work is performed by locally licensed regulatory professionals, and submission dossiers are written directly in the local official language without secondary translation.
Neutral license-holder structures: GRZAN offers holding arrangements that are not tied to any distribution channel, preventing registration certificates from being locked in by channel partners.
Regional leverage: one technical dossier can be reused across Andean Community and Mercosur member states, spreading regional compliance costs.
Full lifecycle support: from classification determination and pathway design through dossier preparation, license holding, customs clearance, post-market vigilance and renewal.

Contact

GRZAN provides registration support in Ecuador for manufacturers, importers and authorized representatives.
Email: info@grzanglobal.com
Service inquiries: Ecuador and Andean market registration plans, license-holder structure design, official fee and timeline estimation

*This volume was prepared by the GRZAN regulatory team; regulatory information verified as of October 29, 2026.*

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.